Investor Presentation

Investor Presentation - Q2FY27 - Revenue ₹10,263 Cr +23.9% y-y; EBITDA ₹2,156 Cr +28.5% y-y; PAT ₹1,124 Cr +32.5% y-y - US formulations grew 25.2% y-y; Europe up 27.5% y-y; Growth Markets stable - EBITDA margin improved to 21.0% (+75 bps y-y) - Net cash position strong at ~US$189 million as of Sep 30, 2026 - Completed acquisition of Lannett, enhancing US presence and complex products - Biosimilars capacity expansion on track for 2027; multiple regulatory filings ongoing - Launched 10 new US products including first NCE ADQUEYTM - Net capex US$89 million focused on capability and new business development - Multiple ANDA filings and approvals progressing across segments